B2M is overexpressed in gliomas, correlates with tumor grade, immune infiltration, and mesenchymal subtype; lower expression predicts longer survival, highlighting B2M as a prognostic biomarker and potential therapeutic target [53,54]. This evidence concerns the gene B2M and central nervous system cancer.